Carregant...
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
BACKGROUND: In this first-in-human, Phase 1 study of a microRNA-based cancer therapy, the recommended Phase 2 dose (RP2D) of MRX34, a liposomal mimic of microRNA-34a (miR-34a), was determined and evaluated in patients with advanced solid tumours. METHODS: Adults with various solid tumours refractory...
Guardat en:
| Publicat a: | Br J Cancer |
|---|---|
| Autors principals: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group UK
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7251107/ https://ncbi.nlm.nih.gov/pubmed/32238921 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0802-1 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|